MB-104 / Fortress - LARVOL DELTA

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates (GlobeNewswire) - "Mustang will discontinue development of its MB-102, its CD123-targeted CAR T cell therapy, as well as its HER2-, CS1- and PSCA-targeted CAR T cell therapy programs, comprising a portion of the Company’s portfolio of CAR T cell therapies being developed by the Company in partnership with City of Hope."

Discontinued • Acute Myelogenous Leukemia • Bladder Cancer • Brain Cancer • Breast Cancer • CNS Tumor • Gastric Cancer • Genito-urinary Cancer • Glioblastoma • Glioma • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Leukemia • Multiple Myeloma • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Urothelial Cancer

[VIRTUAL] MBP104 - Biofilms at the Cutting Edge (WMF 2021) - "By utilizing these methods, developing biofilms have the potential to be phenotypically characterized using metabolic, spatial and tolerance signatures. Upon completion of this In-depth Symposium, the participant should be able to: Illustrate high resolution tools to study bacterial biofilms and how such tools can be used to assess metabolic, spatial and tolerance signatures in biofilms (S) Explain gaps in current methodologies for high resolution studies of biofilms, but also Examine limitations of new technologies presented (S) Discuss applications across multiple models, both environmental and pathogenic platforms (S)"

CS1 Targeted CAR-T Cells (MB-104) for the Treatment of Multiple Myeloma Shows Antitumor Activity Sparing Normal T-Cells Despite the Common Expression of CS1 (ASGCT 2020) - "Here we demonstrate MB-104 does not confer biologically significant fratricide and can be successfully manufactured as evident by viability, growth kinetics and fold expansion despite the shared antigen expression between tumor cells and T cells. CS1 positive T cells are present in culture during the expansion of MB-104 suggesting absence of fratricide. Finally, MB-104 can induce potent anti-tumor cell lyse and proliferate in response to tumor cells."

CAR T-Cell Therapy • IO Biomarker

Mustang Bio announces presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy - "Mustang Bio, Inc…announced two poster presentations at the virtual 23rd Annual Meeting of the American Society of Gene & Cell Therapy ('ASGCT'), being held May 12-15, 2020."

Preclinical • Oncology

Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein (GlobeNewswire, Mustang Bio, Inc.) - Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope, a world-renowned independent cancer research and treatment center, has begun enrolling patients with relapsed or treatment-resistant multiple myeloma in an innovative CS1 chimeric antigen receptor (CAR) T cell therapy (MB-104) trial.

CAR T-Cell Therapy • Enrollment status • P1 data • Preclinical